Iovance Biotherapeutics, Inc. (0JDK.L) LSE

2.37

+0.2(+9.22%)

Updated at September 05 07:07PM

Currency In USD

Iovance Biotherapeutics, Inc.

Address

825 Industrial Road

San Carlos, CA 94070

United States of America

Phone

650 260 7120

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

838

First IPO Date

January 29, 2018

Key Executives

NameTitlePayYear Born
Dr. Frederick G. Vogt Esq., J.D., Ph.D.Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director984,1301974
Mr. Jean-Marc Bellemin M.B.A.Chief Financial Officer, Principal Accounting Officer & Treasurer690,0671972
Dr. Igor P. Bilinsky Ph.D.Chief Operating Officer690,0671973
Dr. Friedrich Graf Finckenstein M.D.Chief Medical Officer764,6341967
Dr. Raj K. Puri M.D., Ph.D.Chief Regulatory Officer833,9841956
Mr. Howard B. Johnson M.B.A.Chief Business Officer01960
Ms. Sara PellegrinoSenior Vice President of Investor Relations & Corporate Communications0N/A
Ms. Tracy WintonExecutive Vice President of Human Resources0N/A
Mr. Kevin SmythExecutive Vice President of Quality0N/A
Mr. Brian Shew M.B.A.Senior Vice President & Head of Digital and Information Technology0N/A

Description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.